Profound Medical Q4 revenue $6M (+43% YoY), net loss $8.2M; installed base 78 TULSA-PRO

Profound Medical Corp.

Q4 revenue record $6.0M (+43% YoY); net loss $8.2M ($0.27/sh) vs $4.9M loss year ago.
FY2025 revenue $16.1M (up from $10.7M); net loss $42.6M ($1.41/sh) vs $27.8M loss.
TULSA-PRO installed base 78, pipeline 110; expects ~120 installs by end of 2026.
Dec 2025 financing: $36M US offering + $6.45M Canadian private placement; cash $59.7M.
Board change: Kris Shah resigns, Frank Baylis appointed; Baylis co-founded Baylis Medical (sold for $1.75B).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Profound Medical Corp. reported the fourth quarter and full year ended December 31, 2025 results: revenue $6.0 million.

Period: the fourth quarter and full year ended December 31, 2025
Revenue: $6.0 million
Result: reported results

Exact text from the filing

Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million.

View on SEC.gov

Browse all earnings releases →

Profound Medical Corp. filing history →

Source: SEC EDGAR

accession 0001171843-26-001362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.